Three recent phase III trials have shown that adjunctive treatment with perampanel—a first-in-class, noncompetitive AMPA antagonist—decreases seizure frequency in patients with refractory focal epilepsy. Although the introduction of perampanel offers more treatment choice for epilepsy, whether it brings urgently needed clinical benefit over existing drugs remains to be addressed.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond
CNS Drugs Open Access 18 June 2021
-
Cortical stimulation in pharmacoresistant focal epilepsies
Bioelectronic Medicine Open Access 25 September 2020
-
Perampanel inhibits calcitonin gene-related peptide release from rat brainstem in vitro
The Journal of Headache and Pain Open Access 12 November 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Löscher, W. & Schmidt, D. Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia 52, 657–678 (2011).
Beyenburg, S., Stavem, K. & Schmidt, D. Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis. Epilepsia 51, 7–26 (2010).
French, J. A. et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology 79, 589–596 (2012).
French, J. A. et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia http://dx.doi.org/10.1111/j.1528-1167.2012.03638.x.
Krauss, G. L. et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology 78, 1408–1415 (2012).
Rogawski, M. A. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr. 11, 56–63 (2011).
Löscher, W. & Schmidt, D. Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation? Epilepsy Res. 17, 95–134 (1994).
Bialer, M. & White, H. S. Key factors in the discovery and development of new antiepileptic drugs. Nat. Rev. Drug Discov. 9, 68–82 (2010).
European Medicines Agency. Fycompa—summary of product characteristics. European Medicines Agency [online], (2012).
Krauss, G. L. et al. Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307. Epilepsia http://dx.doi.org/10.1111/j.1528-1167.2012.03648.x.
Acknowledgements
The authors thank J. A. French for additional information on the perampanel trials, and M. A. Rogawski for discussions and advice during preparation of the figure.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Löscher, W., Schmidt, D. Perampanel—new promise for refractory epilepsy?. Nat Rev Neurol 8, 661–662 (2012). https://doi.org/10.1038/nrneurol.2012.222
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2012.222
This article is cited by
-
Sleep–wake cycle and daytime sleepiness in patients with epilepsy after initiating perampanel as adjunctive therapy
Neurological Sciences (2023)
-
The metabolic basis of epilepsy
Nature Reviews Neurology (2022)
-
The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond
CNS Drugs (2021)
-
Cortical stimulation in pharmacoresistant focal epilepsies
Bioelectronic Medicine (2020)
-
Perampanel inhibits calcitonin gene-related peptide release from rat brainstem in vitro
The Journal of Headache and Pain (2018)